Surgical Considerations in the Treatment of Small Bowel Crohn’s Disease

被引:0
作者
Lillias Holmes Maguire
Karim Alavi
Ranjan Sudan
Paul E. Wise
Andreas M. Kaiser
Liliana Bordeianou
机构
[1] Massachusetts General Hospital,Department of Surgery
[2] University of Minnesota,Department of Surgery
[3] UMass Memorial Medical Center,Department of Surgery
[4] Duke University Medical Center,Department of Surgery
[5] Washington University School of Medicine,Department of Surgery
[6] University of Southern California,Department of Colorectal Surgery
来源
Journal of Gastrointestinal Surgery | 2017年 / 21卷
关键词
Crohn’s disease; Stricturoplasty; Small bowel;
D O I
暂无
中图分类号
学科分类号
摘要
Surgery remains a cornerstone of the management of Crohn’s disease (CD). Despite the rise of biologic therapy, most CD patients require surgery for penetrating, obstructing, or malignant complications. Optimal surgical therapy requires sophisticated operative judgment and medical optimization. Intraoperatively, surgeons must balance treatment of CD complications against bowel preservation and functional outcome. This demands mastery of multiple techniques for anastomosis and strictureplasty, accurate assessment of bowel integrity for margin minimization, and a comprehensive skillset for navigating adhesions and altered anatomy, controlling thickened mesentery, and safely managing the hostile abdomen. Outside of the operating room, a multi-disciplinary team is critical for pre-operative optimization, patient support, and medical management. Postoperatively, prevention and surveillance of recurrence remain a matter of research and debate, and medical options include older drugs with limited efficacy and tolerability versus biologic agents with greater effect sizes and shorter track records. The evidence base for current management is limited by the inherent challenges of studying a chronic disease marked by heterogeneity and recurrence, but also by a lack of prospective trials incorporating both medical and surgical therapies.
引用
收藏
页码:398 / 411
页数:13
相关论文
共 337 条
  • [1] Bernell O(2000)Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn’s disease Br J Surg 87 1697-1701
  • [2] Lapidus A(2014)Incidence and clinical course of Crohn’s disease during the first year—Results from the IBD cohort of the Uppsala region (ICURE) of Sweden 2005–2009 Journal of Crohn’s and Colitis 8 215-222
  • [3] Hellers G(2014)Cumulative incidence of second intestinal resection in Crohn’s disease: A systematic review and meta-analysis of population-based studies Am J Gastroenterol 109 1739-1748
  • [4] Sjöberg D(2013)Outcomes following surgery for perforating Crohn’s disease Br J Surg 100 1344-1348
  • [5] Holmström T(2008)Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn’s disease: A randomized multicenter trial (LIR! C-trial) BMC surgery 8 15-83
  • [6] Larsson M(2016)Post-operative abdominal complications in Crohn’s disease in the biological era: Systematic review and meta-analysis World J Gastrointest Surg 8 274-44
  • [7] Frolkis AD(2008)Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients Gastrointest Surg 12 1738-8
  • [8] Lipton DS(2011)Surgical resection in Crohn’s disease: is immunosuppressive medication associated with higher postoperative infection rates? Colorectal Dis 13 1294-83
  • [9] Fiest KM(2004)Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy Am J Gastroenterol 99 878-8
  • [10] Bellolio F(2012)Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn’s disease Scand J Gastroenterol 47 662-13